Prolor Biotech Climbs Most in Two Weeks on Trial Update

Prolor Biotech Inc. (PBTH) gained the most in two weeks after results from an extended Phase II trial of hGH- CTP human growth hormone showed a single weekly treatment may replace daily injections and was safe.

The shares jumped 3.8 percent, the most since April 22, to 20.89 shekels at the 4:30 p.m. close in Tel Aviv.

To contact the reporter on this story: David Wainer in Tel Aviv at dwainer3@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.